Uncategorized

The past two decades were all about nucleic acid reading and writing. The next is about delivering DNA and RNA, Yogev Debbi, CEO of Mana.bio, told BioSpace in an interview.

Mainz Biomed NV, a molecular genetics diagnostic company specializing in the early detection of cancer, launches a number of events to raise awareness for the importance of early detection of colorectal cancer with physicians and medical professionals, but also with patients, their families, caregivers and the general public in Germany.

Antev Ltd., a late clinical-stage biotech company developing a novel gonadotrophin-releasing hormone antagonist, Teverelix trifluoroacetate, announces that the US Food & Drug Administration has provided written guidance on the company’s proposed Phase 3 pivotal trial design.

Cameras that can scan an entire body in a fraction of a second can give spinal surgeons an accurate assessment of how much range of motion youth with scoliosis have in their torso – a critical piece of information for guiding management of people with the condition, researchers at Hospital for Special Surgery in New

Mesoblast Limited, global leader in allogeneic cellular medicines for inflammatory diseases, announced that the United States Food and Drug Administration’s Office of Therapeutic Products has accepted the Company’s Biologics License Application resubmission for remestemcel-L in the treatment of children with steroid-refractory acute graft versus host disease.

Insurance lobbyists argue that the 1.03% plan increase is insufficient and, in combination with other changes, would actually result in payment cuts.

Medtronic’s device didn’t outperform competing systems being developed by J&J and Boston Scientific, but the results should be enough to secure FDA approval, one analyst wrote.

The results show that low-risk aortic stenosis patients have better outcomes after three years when catheters are used to insert their replacement heart valves, rather than traditional open-heart surgery.

BridgeBio posted data Monday from its small but highly anticipated Phase II study of infigratinib in achondroplasia – a drug that could give BioMarin a run for its money.

FTC Commissioner Christine Wilson said she would have supported an even longer extension since the proposed rule is “a departure from hundreds of years of precedent.”